VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE II CLINICAL TRIAL OF KYLO-11 “LPA SIRNA” IN THE UNITED STATES

VOLUNTARY ANNOUNCEMENT - NALDEMEDINE APPROVED FOR MARKETING IN THE GREATER BAY AREA

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQB3205 “PAN-KRAS INHIBITOR” APPROVED BY THE FDA

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2026

COMPLETION OF SHARE TRANSACTION - ACQUISITION OF 100% EQUITY INTEREST IN HYGIEIA INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME